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Interleukin-36β provides protection 
against HSV-1 infection, but does 
not modulate initiation of adaptive 
immune responses
Katelynn A. Milora1, Siva R. Uppalapati1, Julio C. Sanmiguel2,3, Wei Zou4,5 &  
Liselotte E. Jensen  1,4,6
Interleukin-36 (IL-36) represents three cytokines, IL-36α, IL-36β and IL-36γ, which bind to the same 
receptor, IL-1RL2; however, their physiological function(s) remain poorly understood. Here, the role of 
IL-36 in immunity against HSV-1 was examined using the flank skin infection mouse model. Expression 
analyses revealed increased levels of IL-36α and IL-36β mRNA in infected skin, while constitutive IL-36γ 
levels remained largely unchanged. In human keratinocytes, IL-36α mRNA was induced by HSV-1, while 
IL-1β and TNFα increased all three IL-36 mRNAs. The dominant alternative splice variant of human IL-
36β mRNA was isoform 2, which is the ortholog of the known mouse IL-36β mRNA. Mice deficient in 
IL-36β, but not IL-36α or IL-36γ, succumbed more frequently to HSV-1 infection than wild type mice. 
Furthermore, IL-36β−/− mice developed larger zosteriform skin lesions along infected neurons. Levels 
of HSV-1 specific antibodies, CD8+ cells and IFNγ-producing CD4+ cells were statistically equal in wild 
type and IL-36β−/− mice, suggesting similar initiation of adaptive immunity in the two strains. This 
correlated with the time at which HSV-1 genome and mRNA levels in primary skin lesions started to 
decline in both wild type and IL-36β−/− mice. Our data indicate that IL-36β has previously unrecognized 
functions protective against HSV-1 infection.
Herpes simplex virus-1 (HSV-1) is a common human pathogen that is estimated to be present in up to 90% of 
the adult population1. The virus establishes incurable latent infections in neurons and active disease in the skin or 
mucosa is triggered by, for example, stress and immune suppression. During active disease the virus proliferates in 
epithelial cells leading to infectious viral shedding, tissue damage, and formation of vesicles and lesions1. In healthy 
individuals, lesions heal within 1–3 weeks and complications are rarely seen. However, in immune compromised 
patients and neonates the virus may disseminate to the brain, lung and/or liver with potentially fatal outcomes2–6.
T-cells, NK-cells and antibodies are critically involved in restricting local viral replication and dissemina-
tion to other sites1, 7, 8. However, like most pathogens, HSV-1 has developed immune evasion strategies to pre-
vent or delay detection by the host9. One such mechanism involves retention of the pro-inflammatory cytokine 
interleukin-1β (IL-1β) within infected cells10, 11. Interestingly, HSV-1 infected skin keratinocytes can still release 
IL-1α; a response which appears to promote leukocyte recruitment to infected cells and provides protection from 
viral dissemination12. IL-1α and IL-1β are well known to have pleiotropic effects upon the immune system13. For 
example, they promote inflammation, fever and adaptive immune responses by acting through the same receptor, 
IL-1 receptor type I (IL-1R1)13.
The IL-36 cytokines (IL-36α, IL-36β and IL-36γ) were discovered more than 15 years ago and were, due to 
12–50% sequence homology, immediately recognized as related to IL-1α and IL-1β14, 15. They were momentarily 
named IL-1 family members 6, 8 and 9 (IL-1F6, IL-1F8 and IL-1F9), but later renamed under the common name 
IL-36, in part due to their common use of the IL-1R1 related receptor, IL-1 receptor like 2, IL-1RL216–18, also 
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commonly known as IL-36R. The earlier nomenclature remains unchanged for the mouse genes. The proximity of 
the genes on chromosome 2 in both humans and mice led to the hypothesis that they arose by gene duplication14, 15.
In both humans and mice there are three genes encoding IL-36α, IL-36β and IL-36γ, respectively. At the 
amino acid level, these proteins share approximately 15–85% sequence similarity (Fig. 1). Based on human cDNA 
sequencing, two alternative splice variants of IL-36γ have been identified and entered in GenBank. Compared 
to IL-36γ isoform 1, isoform 2 lacks a small segment near the N-terminus (Fig. 1) due to the omission of an 
exon. Humans may also have two splice variants of IL-36β (Fig. 1) with isoform 2 being most homologous to 
IL-36α and IL-36γ (Fig. 1). Human IL-36β isoform 2 also represents the ortholog of mouse IL-36β (Fig. 1). IL-36β 
isoform 1 arises from the alternative use of 2 exons down-stream of the most 3′ exon utilized by isoform 2. 
Consequently, the C-terminal half of IL-36β isoform 1 is distinctive from the other known IL-36 proteins (Fig. 1a, 
highlighted in red).
During in vivo viral infections, IL-36 expression is induced in epithelial cells by HSV-1 (possibly IL-36α)14, 
rhinovirus (IL-36γ)19 and influenza (IL-36α)20. Further studies have found that expression of IL-36α and IL-36γ 
mRNAs is increased in lung and skin epithelial cells by a range of TLR ligands, e.g., flagellin, double stranded 
RNA, lipopolysaccharide (LPS), lipoprotein (FSL-1) and zymosan21–23. LPS has been reported to also activate 
IL-36α and IL-36β expression in monocytes15. Expression of IL-36γ in neutrophils has been reported as well24; 
however, neutrophils recruited to the skin in patients with the inflammatory condition generalized pustular pso-
riasis do not express IL-36γ25. In the central nervous system, IL-36β can be expressed by neurons and glia cells26.
The IL-1 and IL-36 cytokines lack signal peptides for conventional secretion and are initially synthesized as 
cytosolic proteins. IL-1β is translated as a 269-amino acid protein that, upon cellular activation, is proteolyti-
cally cleaved into the pro-domain (116 amino acids in man) and the functional receptor-binding domain (153 
amino acids). This processing promotes extracellular export13. The IL-1α mRNA is translated into a 271 amino 
acid protein, which has functional activity both as full length and processed forms13. The IL-36 mRNAs encode 
significantly shorter 157–183 amino acids proteins (Fig. 1a). Thus, the IL-36 cytokines were initially believed to 
be synthesized directly as mature proteins, yet without signal peptides14, 15. However, the field has struggled with 
the fact that the recombinant proteins exhibit poor activity, as, for example, noted by Wang et al.26 and Berglof 
et al.27, and required potentially non-physiological concentrations to activate responses in cell culture experi-
ments, e.g., as reported by Towne et al.17 and Carrier et al.28. Using bacterially expressed IL-36 cytokines, it was 
later demonstrated that activity is dramatically improved when a few, very specific, amino acids are removed 
from the N-terminus29. This led to the hypothesis that the IL-36 cytokines require proteolytical processing for 
Figure 1. Protein sequence alignment of human and mouse IL-36 cytokines. (a) Human (h) and mouse (m) 
IL-36 cytokines were aligned using Clustal omega. *conserved residues: Gonnet PAM 250 matrix score > 0.5, 
0 < Gonnet PAM 250 matrix score ≤ 0.5. Amino acid sequence of human IL-36β isoform 1, which diverge 
from the other family members, is shown in red. (b) Neighbor-joining phylogenetic tree showing relationships 
among IL-36 cytokines. The optimal tree with the sum of branch length = 2.69 is shown. The percentage 
of replicate trees in which the associated taxa clustered together in the bootstrap test (1000 replicates) are 
shown next to the branches. The tree is drawn to scale, with branch lengths in the same units as those of the 
evolutionary distances used to infer the phylogenetic tree. The evolutionary distances were computed using the 
Poisson correction method and are in the units of the number of amino acid substitutions per site. (c) Heat map 
showing percentage similarity between the human and mouse IL-36 cytokines.
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activation29. Subsequently, in vitro cleavage by neutrophil proteases has been demonstrated30, 31; however, in vivo 
processing remains to be documented.
The physiological function(s) of the IL-36 cytokines remain poorly understood. Due to increased IL-36α and 
IL-36γ skin expression and presence of loss-of-function mutations in the natural antagonist, IL-36R antagonist 
(IL-36Ra), the IL-36 cytokines are believed to play a pathogenic role in plaque and generalized pustular psoria-
sis16, 25, 32. One such mechanism may involve neutrophil recruitment25, 32–35. Furthermore, in vitro studies suggest 
that the IL-36 cytokines can stimulate maturation of dendritic cells and downstream polarization of naïve T cells 
towards IFNγ producing Th1 cells36–39. This could suggest a role in immune responses directed against microor-
ganisms; yet, documentation of such a function has remained elusive36, 40. Another intriguing aspect of the IL-36 
cytokines is the presence of three genes encoding proteins acting on the same receptor as described above.
With the long-term goals of identifying normal physiological functions and the purpose of maintaining 
the IL-36 gene duplication during evolution, we have started comparing outcomes of challenging IL-36α−/−, 
IL-36β−/− and IL-36γ−/− mice. As part of these studies, we recently reported that inflammation induced by the 
antiviral drug imiquimod requires IL-36α, but neither IL-36β nor IL-36γ41. Interestingly, imiquimod is some-
times used to treat active HSV skin disease caused by strains resistant to acyclovir42–45. Extending upon our 
previous studies, we here examined the role of the individual IL-36 cytokines during HSV-1 infection using the 
flank skin mouse model as our experimental system. Unexpectedly, we found that mice deficient in IL-36β, but 
not IL-36α, developed more severe disease; however, IL-36β was not essential for initiation of adaptive immunity 
against HSV-1. Hence, IL-36β appears to have previously unrecognized functions that protect against the out-
come of HSV-1 infection.
Results
IL-36β deficient mice have increased mortality following HSV-1 infection. Using IL-36α knock-
out (KO) mice, we previously demonstrated that IL-36α is critical for the skin inflammation induced by the 
antiviral drug imiquimod41. In contrast, IL-36β−/− and IL-36γ−/− mice developed the same degree of skin inflam-
mation as wild type mice41. Indirectly, this could suggest a role for one or more IL-36 cytokines in immune 
responses against viruses. Interestingly, when the IL-36s were discovered it was demonstrated that expression 
of one, likely IL-36α, was up-regulated in keratinocytes infected with HSV-114; however, the function was not 
explored. Thus, we examined progression of HSV-1 infection in wild type, IL-36α−/−, IL-36β−/−, and IL-36γ−/− 
mice by employing the flank skin HSV mouse model. We have previously reported that the IL-36 knockout 
(KO) mice have no spontaneous phenotypes precluding this study41. In the flank model, HSV-1 enters sensory 
neurons at the site of primary infection (Fig. 2a, yellow circle). From here it migrates through the neurons to the 
dorsal root ganglia (Fig. 2a, red arrows), where it can establish latency. Subsequently, viral replication, antero-
grade migration (Fig. 2a, blue arrows) and shedding leads to formation of secondary zosteriform lesions along 
the affected neurons (Fig. 2b, days 4–7, note the linear lesion pattern forming 5 days post-infection)1. Using this 
model, we found that IL-36α−/− and IL-36γ−/− mice exhibited the same mortality rate (Fig. 2c, median survival 
time, >16 days) as wild type mice. In contrast, the IL-36β−/− mice revealed significantly reduced survival (Fig. 2c, 
median survival time: 11 days). Fatal outcome in both wild type and IL-36β−/− mice was associated with pro-
gressive weight loss (Fig. 2d). The increased mortality rate of the IL-36β KO mice strongly suggest an important 
involvement of IL-36β in controlling the outcome of HSV-1 infection.
Lethal outcome is associated with bowel dysfunction syndrome in both wild type and IL-36β 
KO mice. It has been reported that mice infected vaginally with HSV-2 (strain 333) develop paralysis, con-
stipation and bladder retention46. These outcomes could be the result of inflammation causing demyelination in 
the nervous system47. Using the flank model and HSV-1 (strain NS), we previously observed a bowel dysfunction 
syndrome evident by greatly enlarged colons and small intestines in moribund wild type and IL-1R1 KO mice12. 
Recently, the lethal outcome of vaginal HSV-1 infection in mice was linked to these phenotypes, as the virus 
spreads through the nervous system resulting in inflammation-mediated damage to the enteric neurons and 
toxic megacolon (constipation)48. Here we found that moribund wild type and IL-36β KO mice exhibited greatly 
enlarged small and large intestines (Fig. 3a). This bowel dysfunction syndrome likely explains the lethal outcome 
in the flank model.
Viral DNA is present in brain, liver and lungs in moribund wild type and IL-36β KO mice. In 
humans HSV can disseminate to internal organs such as the brain, liver and lungs, where it causes organ damage 
leading to significant morbidity and mortality2–6. We previously showed that in the HSV-1 flank model the virus 
disseminates to internal organs such as the brain, liver and lungs12. Furthermore, we reported that IL-1R1 KO 
mice exhibit an increased mortality following HSV-1 infection12 similar to that reported here for IL-36β (Fig. 2c); 
yet levels of viral genomic DNA in internal organs from moribund IL-1R1 deficient mice did not differ from those 
of wild type moribund mice12. Upon analyses of organs from moribund IL-36β KO mice, we found that HSV-1 
genome copy numbers were similar to those found in moribund wild type mice (Fig. 3b). This could suggest that 
HSV-1 disseminates to the same organs in wild type and IL-36β KO mice.
IL-36β KO mice develop antibodies against HSV-1 at the same time as wild type mice. The 
adaptive immune system is essential for immunity against HSV1, 7, 8. In vitro studies have demonstrated that IL-36 
up-regulates expression of MHC class II and CD83 on dendritic cells37, 39, 49; thus, IL-36 may promote the devel-
opment of adaptive immune responses in vivo. In our HSV-1 flank model, mice deficient in B and T cells (RAG1 
KO mice) had a median survival time of 9 days (Fig. 2c). Given the timing of death observed with the RAG1 and 
IL-36β (Fig. 2c) KO mice, we hypothesized that IL-36β protects against HSV-1 by promoting the development of 
adaptive immunity towards the virus. Initial analyses of leukocyte populations in spleens and draining inguinal 
www.nature.com/scientificreports/
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lymph nodes revealed no significant differences in the proportions of granulocytes, antigen presenting cells and 
lymphocytes in wild type and IL-36β KO mice in the presence or absence of infection (Fig. 4a,b).
In mice, antibodies can protect against lethal outcome of HSV infection50, including that caused by the NS 
strain used here51, 52. Hence, we examined the progressive development of HSV-1 antibodies in wild type and 
IL-36β KO mice. HSV-1 gD has been reported to be the major antigen towards which early antibodies are directed 
during a primary HSV infection (see ref. 51 for refs.). In agreement with this, we observed potent reactivity 
towards an approximately 43 kDa protein band likely representing HSV-1 gD (Fig. 4c). Similar banding patterns 
were observed in wild type and IL-36β KO mice (Fig. 4c). Quantitative analyses (Fig. 4d) revealed appearance of 
increased antibody levels already at day 5 in both wild type and IL-36β KO mice (Fig. 4d). These levels increased 
up to day 9 when RAG1−/− died; however, no statistically significant differences between wild type and IL-36β 
KO mice were detected (Fig. 4d). This outcome demonstrates that IL-36β plays no role in initiating a primary 
antibody response in the present model system.
Wild type and IL-36β KO mice develop gB(498–505) specific CD8+ cells at the same time. CD8+ 
cells can kill HSV-1 infected cells8, and start clearing the primary HSV-1 infection in the mouse flank skin model 
as early as day 5 post-infection53. Since IL-36β deficient mice developed antibodies at the same time as wild type 
mice, we next examined their ability to develop HSV-1 specific CD8+ cells. Overall levels of the major T cell pop-
ulations were indistinguishable in wild type and IL-36β KO spleens and draining inguinal lymph nodes in both 
uninfected and infected mice (Fig. 5a). In mice, the majority of HSV-1 specific CD8+ cells are directed against 
the epitope gB(498–505) comprising the sequence SSIEFARL54. To address if the initiation of the development of 
these cells requires IL-36β, we examined levels of HSV-1 gB(498-505) specific cells 6 days post-infection. Since 
this is a very early time point, numbers of these cells were expected to be low. In both wild type and IL-36β KO 
mice, the percentage of CD8+ cells specific to gB(498-505) increased significantly in both the draining inguinal 
lymph nodes and the spleens post-infection (Fig. 5b,c); however, no significant differences between wild type 
Figure 2. IL-36β, but not IL-36α or IL-36γ, provides protection against lethal outcome of HSV-1 infection. (a) 
Illustration of inoculation site (yellow circle) and directions of retrograde (red arrows) and anterograde (blue 
arrows) migration of HSV-1 through neurons. (b) Progression of disease in wild type mice (C57BL/6) infected 
with 1.5 × 106 PFU HSV-1 on flank skin (white arrowhead) at day 0 is depicted at the indicated time-points. 
Black arrowhead points to early secondary lesion appearing along sensory neurons (note the linear progression 
of the lesions). Ruler used for quantification of lesion sizes visible in day 9 image. Image of gravestone can be 
found at: https://freeclipartnow.com/holidays/halloween/graveyard/R-I-P-gravestone.jpg.html. (c) Wild type 
(C57BL/6, green), IL-36α−/− (red), IL-36β−/− (blue), IL-36γ−/− (black), and RAG1−/− (brown) mice were 
infected with 1.5 × 106 PFU HSV-1 on the right flank on day 0, and survival monitored for 16 days. n indicates 
number of mice per group. Data shown is pooled from 6 independent experiments. Statistical significance was 
determined using Mantel-Cox and Gehan-Breslow-Wilcoxon tests; ****p < 0.0001. (d) Wild type (C57BL/6, 
n = 18, black lines and symbols) and IL-36β−/− (n = 8, red lines and symbols) mice were infected with HSV-1 
as described above. Pooled weight data (means ± SD) of survivors (closed symbols) and mice progressing 
to become moribund (open symbols) from two independent experiments is shown. *p < 0.05 (comparing 
survivors to moribund within each strain); **p < 0.01; ***p < 0.001.
www.nature.com/scientificreports/
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and IL-36β KO mice were detected (Fig. 5b,c). This suggests that IL-36β does not regulate processes required for 
initiation of CD8 mediated cellular immunity.
HSV-1 replication appears to progress similarly at the site of primary infection in wild type and 
IL-36β−/− mice. The similar induction of adaptive immune responses in wild type and IL-36β KO mice 
(Figs 4, 5) could suggest comparative abilities to clear viral infection. Analyses of HSV-1 genome copy num-
bers (Fig. 6) in primary infections sites were found to be not statistically significantly different in the wild type 
and IL-36β KO mice on days 3 and 5. This could suggest that HSV-1 replicates in the skin at similar rates in 
both strains. Furthermore, the viral genome copy numbers started to decrease at the same time, i.e., leading to 
a significant reduction in HSV-1 genome copy numbers from day 5 to day 7 (Fig. 6). The timing of this decrease 
correlated with induction of early HSV-1 specific antibodies (Fig. 4). This provides further evidence that adaptive 
immune responses aimed at clearing the skin infection are equally well initiated in the wild type and IL-36β KO 
mice.
IL-36β deficient mice develop more severe secondary zosteriform skin lesions. An interesting 
aspect of the flank model of HSV-1 skin infection is the re-dissemination of the virus from the dorsal root gan-
glion, through the sensory neurons, to the skin, where it causes the formation of secondary zosteriform lesions 
along the dermatome several days after primary infection (Fig. 2a,b). In IL-1R1 KO mice these secondary lesions 
appear at the same time as in wild type mice12. Furthermore, the lesions progress in size in a similar manner12. 
Interestingly, in the present study we found that these zosteriform lesions emerged approximately at the same 
time in wild type and IL-36β KO mice (Fig. 7, day 5) suggesting that the virus migrates through the neurons at 
the same rate. However, the secondary lesions progressed to become significantly larger in IL-36β KO mice than 
in wild type (Fig. 7, days ≥ 6). This may implicate IL-36β in mechanisms aimed at limiting wound progression as 
the virus reemerges from the neurons.
Levels of IFNγ-producing CD4+ cells are similar in wild type and IL-36β KO zosteriform 
lesions. IFNγ-producing CD4+ cells provide protective immunity against HSV infections in peripheral epi-
thelial tissues55, 56. Since IL-36 has been shown to promote differentiation of naïve T cells into IFNγ-producing 
Th1 cells37, 57, we hypothesized that the larger zosteriform lesions could be due to reduced levels of these cells 
in the skin. Significantly increased levels of IFNγ-producing CD4+ cells were found in skin surrounding early 
secondary lesions compared to uninfected and primary infection sites (Fig. 8). However, no statistically sig-
nificant differences in IFNγ-producing CD4+ cell levels were found when comparing wild type to IL-36β KO 
mice (Fig. 8). This suggests that IL-36β KO mice have an uncompromised capacity to activate and/or recruit 
IFNγ-producing CD4+ cells.
IL-36 expression is induced during in vivo infection in mice. To possibly explain the specific role of 
IL-36β, but not IL-36α and IL-36γ, in protection against HSV-1 infection (Fig. 2c), we examined in vivo IL-36 
Figure 3. Mortality is associated with viral dissemination to multiple organs. (a) Representative images 
of bowels of moribund wild type and IL-36β−/− (Fig. 2) mice are shown. (b) Wild type (black circles) and 
IL-36β−/− (open triangles) mice were infected with 1.5 × 106 PFU HSV-1 on the right flank. Organs were 
collected from moribund mice, homogenized and HSV-1 genome copy numbers determined by QPCR. Each 
symbol represents a single mouse. Data is pooled from two independent experiments. No statistical significant 
differences were observed between wild type and IL-36β deficient mice.
www.nature.com/scientificreports/
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expression in the skin during HSV-1 infection (Fig. 9a–c). Expression of the IL-36α and IL-36β mRNAs was 
dramatically increased (approximately 20–40-fold) in primary lesions starting at day 3, and levels remained ele-
vated through day 7 (Fig. 9a,b). In contrast, the IL-36γ was only modestly induced (2-3-fold) by day 7 (Fig. 9c). 
Induction of the IL-36 mRNAs appeared delayed compared to viral replication as measured through levels of 
Figure 4. IL-36β−/− mice develop antibodies against HSV-1 at the same time as wild type mice. (a) Wild 
type and IL-36β−/− mice were infected with HSV-1 (n = 5 per group) or left uninfected (n = 2–3 per group). 
Cells were isolated from spleen and draining inguinal lymph nodes 6 days post-infection and analyzed by 
flow cytometry. Granulocyte, lymphocyte, and antigen presenting cell (APCs) populations were quantified 
via gates depicted on representative images of forward scatter and side scatter. (b) Graphic representation of 
data (means ± SD) from a. #p > 0.05. Representative experiment of 3. (c and d) Wild type (as labeled in c, black 
circles in d) and IL-36β−/− (as labeled in c, open triangles in d) mice were infected with HSV-1 and serum 
collected at the indicated time-points. (c) Reactivity of mouse sera against HSV-1 infected HaCaT protein 
lysate was examined by Western blotting. The HaCaT protein lysate was separated by SDS-PAGE using a gel 
with a single approximately 7 cm wide well. After transfer to a PVDF membrane, multiple strips approximately 
2 mm wide were cut and used for incubation with individual sera. Approximate positions of protein markers 
are shown. (d) Reactivity of mouse sera against HSV-1 gD were determined by direct ELISA. Log2 reciprocal 
values of end-point titers are depicted. Gray box indicates background signal against trace E. coli proteins. 
No statistically significant differences were observed between wild type and IL-36β deficient mice (#) despite 
significant increases in anti-gD titers in both strains (**p < 0.01 (compared as indicated); ***p < 0.001). Each 
symbol represents a single mouse.
www.nature.com/scientificreports/
7Scientific RepoRts | 7: 5799  | DOI:10.1038/s41598-017-05363-4
Figure 5. Wild type and IL-36β KO mice have equal numbers of early HSV-1 gB(498-505) specific CD8+ 
cells. Wild type and IL-36β KO mice were infected with HSV-1 (n = 5 per group) as described in Fig. 2 or left 
uninfected (n = 2–3 per group). Cells were isolated from spleen and draining inguinal lymph nodes 6 days 
post-infection and analyzed by flow cytometry. (a) Total number of CD3, CD4 or CD8 positive cells per organs 
are shown. (b) Cells were examined following initial gating of the CD3+ population. The square gates identify 
the gB(498–505)/CD8 double positive cells. Numbers above the gates indicate percentage gated cells of all 
CD8+ cells. (c) Graphic representation of gB(498–505) specific CD8+ T cells (means ± SD) quantified in b. One 
representative experiment of 3 is shown. #p > 0.05; *p < 0.05, **p < 0.01.
www.nature.com/scientificreports/
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HSV-1 gD mRNA (Fig. 9d). Furthermore, the IL-36 mRNA levels remained elevated by day 7 (Fig. 9a–c), as viral 
levels decreased (Fig. 9d). The HSV-1 gD mRNA levels, including the observed decrease in the HSV-1 gD mRNA 
levels at day 7, correlate with the observed HSV-1 DNA genome copy numbers (Fig. 6). This could suggest that 
the induction of IL-36 expression is secondary to the infection, i.e., not a direct response to HSV-1.
Next the relative expression of the three IL-36 mRNAs was examined (Fig. 9e). Analyses in uninfected skin 
revealed that the IL-36γ mRNA is constitutively expressed at approximately 10-fold higher levels than the IL-36α 
and IL-36β mRNAs (Fig. 9e). However, due to the strong induction of the IL-36α and IL-36β mRNAs (Fig. 9a,b), 
a trend towards the IL-36β mRNA being the dominant form at day 3 may be detected.
IL-36α, but not IL-36β and IL-36γ, expression is induced in human keratinocytes during in vitro 
HSV-1 infection. Previously, we showed that human primary keratinocytes have high levels of pre-formed 
IL-1α that are released upon HSV-1 infection12. In contrast, unstimulated keratinocytes express only very low 
levels of IL-36β mRNA; however, the expression is increased approximately 10-fold upon poly(I:C) treatment22. 
Figure 6. Primary skin infection site viral genome copy numbers are indistinguishable in wild type and IL-36β 
KO mice. Wild type (black circles) and IL-36β−/− (open triangles) mice were infected with HSV-1 on the flank 
skin as described in Fig. 2. The center of primary infection sites were collected with 4 mm punch biopsy tools at 
the indicated time-points. Viral genome copy numbers were determined by QPCR. Each symbol represents a 
single mouse. **p < 0.01; #p > 0.05.
Figure 7. IL-36β deficient mice develop more severe secondary zosteriform skin lesions. (a) Wild type and IL-
36β KO mice were infected with HSV-1 as described in Fig. 2. Male and female wild type and IL-36β KO mice 
were anesthetized and photographed at day 6 post-infection. (b) Wild type (open circles, n = 6) and IL-36β 
KO (black circles, n = 5) mice were infected with HSV-1 as described in Fig. 2 and progression of secondary 
zosteriform lesions photo-documented for 15 days as illustrated in a and Fig. 2. Lesions were sized using ImageJ. 
†, all mice dead; ***p < 0.001.
www.nature.com/scientificreports/
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Here we found that HSV-1 infection induced expression of IL-36α (Fig. 10a). However, we observed no signifi-
cant increase in the IL-36β and IL-36γ mRNAs (Fig. 10b,c).
Cytokines induce expression of all three IL-36 mRNAs. The delayed in vivo induction of the IL-36 
mRNAs could suggest secondary responses. Expression of the IL-36 mRNAs can be induced by cytokines such 
as IL-1, IFNγ (IL-36β only) and TNFα21, 28. We previously showed that these cytokines can induce chemokine 
expression in keratinocytes in additive and synergistic manners58. Here, we found that IL-1β and TNFα signif-
icantly induced all three IL-36 mRNAs (Fig. 10d); sometimes with synergistic effects (IL-36α mRNA 24 hours, 
Fig. 10d). In some (not shown), but not all (Fig. 10d), experiments we observed increased expression of the 
IL-36β mRNA in response to IFNγ. Overall, the IL-36α and IL-36γ mRNAs appeared the most dramatically 
induced with IL-36γ exhibiting the highest levels of expression (Fig. 10d).
IL-36β isoform 2 is the major IL-36β isoform expressed in human keratinocytes. Interestingly, 
two alternative splice variants of human IL-36β mRNA have been sequenced (Fig. 1). Isoform 2 represents the 
ortholog of the known mouse IL-36β mRNA (Fig. 1), whereas isoform 1 is substantially distinct from the other 
IL-36 cytokines (Fig. 1). Isoform specific analyses of human keratinocyte mRNA revealed that the IL-36β isoform 
2 mRNA was expressed at dramatically higher levels (>50-fold at all time-points and treatments) than IL-36β 
isoform 1 (Fig. 10d). This suggests that most of the IL-36β expressed by keratinocytes will have activity similar to 
those of IL-36α and IL-36γ.
Discussion
A role for the IL-36s in immunity against microorganisms has been suggested by their induction in epithelial 
cells in response to several pathogen associated molecular patterns in vitro21, 22 as well as HSV-1, rhinovirus 
and influenza in vivo14, 19, 20. However, the physiological functions of the IL-36s during infections remain poorly 
understood. Using KO mice for each individual IL-36 cytokine, we found that IL-36β, but not IL-36α or IL-36γ, is 
critically involved in protecting against the outcome of HSV-1 skin infection. We specifically observed that IL-36β 
KO mice develop larger skin lesions (Fig. 7) and have decreased survival (Fig. 2c). This suggests an essential role 
for IL-36β in controlling the outcome of the viral infection.
The IL-36s can activate dendritic cells in vitro36–39, 57 and in vivo in an experimental model of psoriasis, a 
chronic inflammatory skin condition59. This could suggest that the IL-36s play a role in activating the adaptive 
immune response. Interestingly, we find that IL-36β KO mice start to clear the viral skin infection as quickly as 
the wild type mice (Fig. 6, day 7; Fig. 9d, day 7). Furthermore, we were unable to detect differences in levels of 
antibodies (Fig. 4c,d), gB(498-505) specific CD8+ (Fig. 5b,c) and IFNγ-producing CD4+ cells (Fig. 8) in wild 
type and IL-36β KO mice. This suggests that IL-36β does not play a significant role in initiating adaptive immu-
nity against the examined immunogens in the presently used model. Since phenotypic differences are observed 
between wild type and IL-36β KO mice, IL-36β must have other essential physiological functions during HSV-1 
infection. Although IL-36β did not contribute to the development of adaptive immunity in the present stud-
ies, the IL-36 cytokines may still be involved in these responses. Our initial working hypothesis was that the 
IL-36 cytokines could overcome HSV-1 immune evasion that inhibits the function of IL-1β10, 11 and presumably 
IL-18 by similarity. IL-1α and IL-33 are related cytokines that are highly expressed in keratinocytes and play 
a significant role in immunity against HSV infection12, 60. The presence of these cytokines could be enough to 
initiate adaptive immunity in the present HSV infection model. Further studies involving mice unable to signal 
via all these cytokines will be required to test this possibility. In addition, IL-36β may play a role in recruitment 
of immune cells (discussed below) and maturation of the immune response. We here examined early immu-
nity against the dominant antibody gD (Fig. 4d) and CD8+ gB (Fig. 5b,c) immunogens. However, over time the 
Figure 8. Number of IFNγ-producing CD4+ cells are similar in wild type and IL-36β KO zosteriform lesions. 
Wild type (black bars) and IL-36β KO (open bars) mice were infected with HSV-1 (n = 10 per group) or left 
uninfected (n = 3–5 per group). Skin was collected 6 days post-infection. Primary lesion sites were collected 
with 8 mm biopsy punches at the center of the initial infection sites. Upper and lower secondary lesions (Fig. 2b) 
were excised and pooled. Number of IFNγ-producing CD4 + cell were determined using ELISpot assays. 
Representative data (means ± SD) from one of two experiments are shown. #p > 0.05; *p < 0.05; **p < 0.01.
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immune response develops to enhance epitope affinity and diversity. Future analyses of such responses may reveal 
if IL-36β regulates these processes. Similar analyses of IL-36α and IL-36γ functions should also be performed in 
conjunction with quantification of IL-36 protein levels and proteolytical activation.
The specific role of IL-36β, but not IL-36α and IL-36γ, in protection against lethal outcome of the HSV-1 
infection (Fig. 2c) is intriguing. Using a vaginal model of HSV-1 infection, the lethal outcome of the disease in 
mice has recently been linked to dissemination of the virus to the enteric nervous system, resulting in inflamma-
tion mediated nerve damage, constipation and toxic megacolons48. In the HSV-1 flank skin infection model used 
here, moribund mice exhibit a gastro-intestinal phenotype (Fig. 3a) suggesting a similar loss of peristalsis leading 
to death. Furthermore, HSV-1 DNA can be detected in several vital organs such as the brain, liver and lungs 
(Fig. 3b). Interestingly, neurons can express IL-36β, and astrocytes and microglia have the receptor for IL-36, 
IL-1RL226, 27. Hence, it is possible that IL-36β protects against lethal outcome of HSV-1 infection (Fig. 2c) by 
modulating the ability of the virus to spread and/or replicate in the nervous system. The cellular source(s) of IL-36 
and induction pathways in the skin, and possibly the nervous system, remain to be determined. It is conceivable 
Figure 9. IL-36 mRNA expression is induced in vivo. (a–d) C57BL/6 mice were infected with HSV-1 (black 
symbols) or left uninfected (open symbols). At the indicated time-points primary or mock lesions were 
collected at the center using 4 mm punch biopsies. IL-36 (a–c) and HSV-1 gD (d) mRNA levels determined 
by real-time PCR using GAPDH as the housekeeping gene against which individual mRNA levels were 
standardized. Fold changes in IL-36 mRNA levels were calculated against uninfected skin. Fold changes in 
HSV-1 gD mRNA levels were calculated against levels at day 1. Data shown is pooled from three independent 
experiments. (e) IL-36α (open bars), IL-36β (blue bars) and IL-36γ (red bars) mRNA levels were recalculated 
(data from a–c) relative to levels of the IL-36α mRNA in uninfected mice. *p < 0.05; **p < 0.01; ***p < 0.001; 
ND, not detected.
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that the IL-36s act in local microenvironments, and thereby regulate very different physiological responses to 
infections. Further studies will be required to establish these mechanisms and functions.
The IL-36s promote neutrophil recruitment in different types of psoriasis25, 41. Neutrophils play an important 
role in guiding CD8+ cells to sites of influenza infection in the lungs61, and HSV-1 skin lesions are well known 
to be rich in neutrophils (see Wojtasiak et al.62 for refs). However, intradermal administration of IL-36α does 
not promote recruitment of CD8+ cells39, and removal of neutrophils does not affect the outcomes of HSV-1 
skin infection62. Hence, neutrophils may have distinct anti-viral functions in the lungs that are not observed in 
the skin. While this manuscript was being prepared, it was reported that mice deficient in the receptor for IL-36, 
IL-1RL2 (also known as IL-36R), are protected from the lethal outcome of lung influenza virus infection20. The 
reduced mortality was associated with decreased lung inflammation, e.g., neutrophil infiltration, and tissue dam-
age20. Furthermore, the virus induced inflammation was IL-36α dependent20. The latter is in agreement with our 
studies in the imiquimod skin inflammation model, where neutrophils are recruited in response to increased 
IL-36α expression41. However, the former is the opposite outcome, compared to the increased mortality seen 
here in the HSV-1 infection model in the absence of IL-36β signaling (Fig. 2c). The distinct phenotype in the HSV 
model used here may be linked to a unique role of IL-36β in the nervous system as discussed above. However, 
IL-36β also appears to have a distinct role in the skin. If the observed skin lesions (Figs. 2b and 7) were caused by 
inflammation induced by IL-36β, we would expect IL-36β KO mice to have smaller lesions than wild type; how-
ever, larger lesions are in fact observed (Fig. 7). In vitro studies with keratinocytes may reveal if IL-36β can mod-
ulate innate immunity in these cells. Additional studies of other viruses may also determine if these are functions 
specific to HSV or neurotropic pathogens, or if they represent universal protective mechanisms.
IL-36γ was shown recently to promote wound healing in the gut in experimental models of inflammatory 
bowel disease63, 64. IL-36 could have a similar function in the skin during HSV-1 infection. Such a wound healing 
property could explain, at least in part, why lesions are larger in IL-36β KO mice than wild type (Fig. 7), and 
is supported by the extended expression of IL-36 at day 7 post-infection (Fig. 9a–c), when levels of virus are 
already declining (Figs 6 and 9d). It is also conceivable that IL-36 expression (Fig. 9a–c) is induced by wound 
healing responses and not the infection per se. This could explain the paradox that the IL-36β mRNA is induced 
in vivo (Fig. 9b), but not during an in vitro infection (Fig. 10b). However, since IL-36β deficient lesions progress 
to become larger (Fig. 7), not merely heal poorly, IL-36β must have additional activity aimed at restricting the 
virus or lesion progression. This could involve an innate immune mechanism that restricts the ability of HSV-1 
to spread laterally within the proliferating layer of keratinocytes in the skin. Further studies of how IL-36β con-
trols HSV-1 infection, and IL-36 promote wound healing will be needed to determine the specific mechanism(s) 
involved.
Figure 10. Human IL-36 mRNAs are differentially induced in response to HSV-1 infection and cytokines. 
Human primary keratinocytes were infected with HSV-1 (a–c) or treated with medium only, 10 ng/ml IL-
1β, 20 ng/ml IFNγ and/or 50 ng/ml TNFα (d) as indicated. IL-36α, IL-36β (isoform 1 and 2 in d) and IL-36γ 
mRNA levels were determined by real-time PCR and standardized against GAPDH levels. (a–c) Fold changes in 
IL-36 expression were calculated against medium only treated samples at the same time-point. (d) Proportional 
expression of IL-36 levels are graphed as log2(Ct-IL-36−Ct-GAPDH). Representative data from one of at least three 
independent experiments is shown as means ± SD. *p < 0.05 (compared to medium only at the same time-
point); **p < 0.01; ***p < 0.001.
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In summary, IL-36β clearly plays a critical role in controlling the outcome of HSV-1 infection (Figs. 2 and 7); 
however, further studies will be necessary to define the mechanisms whereby IL-36β acts, and how it is activated 
and released from cells.
Methods
Virus and viral titers. Dr. Harvey M. Friedman (University of Pennsylvania, Philadelphia, PA) kindly pro-
vided the clinical HSV-1 isolate NS65. Virus was propagated in Vero cells obtained from ATCC, Manassas, VA. 
Viral titers were determined by plaque assays as follows: Virus was diluted in 10-fold serial dilutions in DMEM 
serum-free medium (Invitrogen, Carlsbad, CA). Vero cells grown in a 12-well plate were washed with PBS imme-
diately before infection. Cells were incubated with 200 μl viral dilutions for 1 hour at 37 °C with gentle rocking of 
the plate every 10 minutes. After infection, cells were washed with PBS and overlayed with a 1:1 mixture of 1.2% 
low melting temperature agarose and 2X medium (DMEM low-glucose (Sigma-Aldrich, St. Louis, MO), supple-
mented with 10% fetal bovine serum (FBS, Atlanta Biologicals, Lawrenceville, GA) and gentamicin (Invitrogen). 
Plaques were counted approximately 48 hours post-infection.
Mice. Wild type C57BL/6 and RAG−/− mice were obtained from the Jackson Laboratory, Bar Harbor, ME, 
and bred in-house. The IL-36α−/−, IL-36β−/−, and IL-36γ−/− mice, originating from GlaxoSmithKline (NC), The 
Knockout Mouse Project (UC Davis, CA), and Mutant Mouse Regional Resource Center (University of North 
Carolina, NC), respectively, were recently described and have no apparent spontaneous phenotypes41. All strains 
were maintained on the C57BL/6 background. All procedures involving mice were approved by the Temple 
University Institutional Animal Care and Use Committee and in compliance with the U.S. Department of Health 
and Human Services Guide for the Care and Use of Laboratory Animals.
Mice were genotyped using ear punches processed as previously described66. The primers used were: 
Il1f6-forward, 5′ GTCACAGTTAAGGCGTTCACC 3′; Il1f6-wild-type-reverse, 5′ AAGGGCCAGGGCTACT 
CAC 3′; Il1f6-KO-reverse, 5′ CTTAATATGCGAAGTGGACCTG 3′; Il1f8-forward, 5′ CTTAGGGATTGCTGT 
CCTTG 3′; Il1f8-wild type reverse, 5′ GTGTTATGATTCGGTTCCCAC 3′; Il1f8-KO-reverse, 5′ GATAGGTCA 
CGTTGGTGTAG 3′; Il1f9-wild-type-forward, 5′ CTGGGCTATTTGTATCTTCA 3′; Il1f9-wild-type-reverse, 
5′ CACACCTGCTGGTCCAAGTC 3′; Il1f9-KO-forward, 5′ GGCGGATTTCTGAGTTGGAG 3′; Il1f9-KO-reverse, 
5′ GCAGCGCATCGCCTTCTATC 3′; Il1r1-forward, 5′ GAGTTACCCGAGGTCCAGTGG 3′; Il1r1-KO-reverse, 
5′ GAATGGGCTGACCGCTTCCTCG 3′; and Il1r1-WT-reverse, 5′ CCGAAGAAGCTCACGTTGTCAAG 3′.
In vivo HSV-1 infections. Male and female mice were bred in house in a pathogen-free animal facility 
and used for experiments. Mice were matched for age (7–12 weeks) and sex in each individual experiment. The 
infection protocol was obtained from Dr. Friedman52. Mice were denuded the day before infections by sequential 
shaving and epilating cream application. Cream was removed by rinsing with water. Scratch inoculations were 
performed with 1.5 × 106 PFU HSV-1 on the right flank. Mice were photographed next to a ruler every second 
day. Image pixels were converted to mm using Image J (https//imagej.net/Welcome) and the depicted ruler. Skin 
lesions were outlined and sized in Image J. Blood was collected by cardiac puncture immediately following eutha-
nasia and serum stored at −20 °C.
Cell culture and treatments. Pooled human neonatal primary keratinocytes (Thermo Fisher Scientific, 
Carlsbad, CA) were maintained in Defined Keratinocyte Serum Free Medium supplemented with 50 μg/mL gen-
tamicin (Invitrogen). HaCaT cells (provided by Dr. Meenhard Herlyn, Wistar Institute, Philadelphia, PA) were 
maintained in Dulbecco’s modified Eagle’s medium (Thermo Fisher Scientific) supplemented with 10% (vol./vol.) 
FBS and 50 μg/ml gentamicin. Cells were treated with cytokines as previously described58.
Western blotting. HaCaT cells infected with HSV-1 were detached from growth area and loaded on a 
single-well NuPAGE 10% Bis-Tris gel (Thermo Fisher Scientific) using standard SDS-PAGE reducing conditions. 
Proteins were transferred to a PVDF membrane and approximately 2 mm wide strips cut from the top to the bot-
tom. Sera from HSV-1 infected mice were diluted 1:250 in PBS, 1% BSA, 0.05% tween 20, and individually probed 
on a strip each overnight. Strips were washed and developed with anti-mouse Ig conjugated with horseradish 
peroxidase (GE Healthcare Life Sciences, Pittsburgh, PA) and enhanced chemiluminescence.
HSV-1 genome copy numbers in tissue. Mouse tissue samples were immediately frozen on dry 
ice following euthanasia. Primary infection sites were collected using 4-mm biopsy punches (Miltex, York, 
PA). Tissue was ground into a powder over dry ice with autoclaved mortar and pestle. DNA was extracted 
from tissue using the Qiagen DNeasy Blood & Tissue kit according to manufacturer’s instructions (Qiagen, 
Valencia, CA). Viral genome copy numbers were determined using quantitative real-time PCR with 500 ng 
DNA per reaction and the following primer/probe set: 5′ CGACCAACTACCCCGAT 3′ (forward primer), 5′ 
CACTATGACGACAAACAAAATCAC 3′ (reverse primer), and VIC-CAGTTATCCTTAAGGTCTC-MGBNFQ 
(probe). TaqMan Gene Expression Master Mix (Applied Biosystems, Foster City, CA) was used for PCR amplifi-
cation on an Applied Biosystems StepOnePlus Real-Time PCR System. A DNA standard was generated using the 
above primer pairs and an aliquot of NS. The generated PCR product was cloned into the pGEM-T Easy vector 
(Promega, Madison, WI) and a single cloned confirmed by full length sequencing. The plasmid was linearized 
with PstI restriction enzyme and quantified by nanodrop, after which genome copy numbers/μl were calculated. 
Serial dilutions (10-fold) were used to generate a standard curve from 1 × 107 copies to 1 copy.
Cloning, expression and purification of recombinant HSV-gD protein. The HSV-1 gD gene 
sequence (GenBank accession number: SBS69688) was amplified from DNA isolated from infected tis-
sue using the primers 5′ CATGGGGTCCGCGGCAAATATG 3′ and 5′ GAGGACGGCTGGTCGTCTTCC 
www.nature.com/scientificreports/
13Scientific RepoRts | 7: 5799  | DOI:10.1038/s41598-017-05363-4
3′. BamHI and EcoRI restriction sites were added to the N and C terminal ends of the gD gene by PCR using 
the primer pair 5′ AGTAGGATCCCATGGGGTCCGCGGCAAATATG 3′ and 5′ GAAGGAATTCGAG 
GACGGCTGGTCGTCTTCC 3′. The restriction site flanked gD amplicon was directionally cloned into pHUTA 
vector67 and confirmed by full length sequencing. The recombinant vector was transformed into E. coli BL21 
DE3 cells. Overnight cultures were re-inoculated into fresh LB broth (1:100) and incubated at 37 °C with shaking 
until an OD of 0.6 was reached. The culture was induced with 1 mM isopropyl β-D-thiogalactopyranoside for 5 h. 
Bacteria were harvested by centrifugation at 10,000 × g for 10 min, resuspended in PBS (pH 7.4) and analyzed for 
expression by Western blot using antibodies against 6x His tag on the recombinant protein (Anti his probe-HRP: 
Santa Cruz Biotechnology, Santa Cruz CA). Recombinant gD protein was purified under denaturing conditions 
by immobilized metal affinity chromatography using Ni2+-NTA slurry (Thermo Fisher Scientific) according to 
the manufacturer’s protocol. The purified protein was ascertained by SDS-PAGE, and quantified by BCA protein 
assay against known bovine serum albumin standards.
HSV-1 glycoprotein D (gD) direct ELISA. Anti-HSV-1 gD titers were measured using 2-fold serial dilu-
tions of sera by indirect ELISA. Microtiter plates were coated overnight with 50 µl of 100 µg/ml gD antigen solu-
tion in coating buffer (0.08 M sodium carbonate and 0.02 M sodium bicarbonate, pH-9.6). Coated plates were 
blocked with 3% bovine serum albumin in PBS at room temperature for 3 h. Serially diluted test sera were added 
to each well and incubated at room temperature for 2 h. Wells were washed three times with PBST (PBS + 0.5% 
Tween 20) and incubated with horse radish peroxidase conjugated polyvalent anti-mouse Ig antibody for 1 hour 
in darkness. Wells were developed with 2,2′-azino-bis(3-ethylbenzothiazoline-6-sulphonic acid) substrate. OD 
values were measured at 492 nm, and end-point titers determined as the highest antibody dilution whose mean 
O.D. was at least twice more than the mean O.D. value of the negative control (PBS).
Flow cytometry. Spleen and the draining inguinal lymph node were harvested from euthanized mice 6 
days post-infection. Organs were pushed through 70 um cell strainers (one strainer per organ per mouse), into a 
50 ml tube and washed with PBS. Spleen cells were treated with RBC lysis buffer (eBiosciences, Waltham, MA). 
Cells were resuspended in 5% FBS/PBS and counted by hemacytometer. Cells (1 × 106) from each organ was 
plated into a 96-well conical bottom plate and spun down. Cells were washed 2 times with 0.1% BSA/PBS. Cell 
pellets were incubated with a 1/40 dilution R-PE labeled H-2Kb SSIEFARL Pro5 MHC Pentamer (ProImmune, 
F188-82A-D, Sarasota, FL), for 10 minutes at room temperature in the dark. Cells were washed 3 times with 0.1% 
BSA/PBS, then incubated with cocktail containing 1/80 dilution APC-CD3 (eBiosciences anti-mouse CDS APC 
clone: 17A2), 1/200 dilution PeCy7-CD4 (BD pharmingen rat anti-mouse CD4 clone:RM4-5, San Jose, CA) and 
1/100 dilution FITC-CD8 (ProImmune rat anti-mouse CD8 FITC (KT15) IgG2a), for 30 minutes at 4 °C in the 
dark. Cells were washed 3 times with 0.1% BSA/PBS and fixed in 2x paraformaldehyde diluted in 0.1% BSA/PBS.
Cells were evaluated on a BD FACSCanto utilizing FACSDiva software. 1 × 105 events were collected for each 
sample gated on primarily live cells using the forward scatter channel (FSC). FlowJo v:10.1r5 was used to analyze 
data. Samples were gated for total cell populations (lymphocytes, granulocytes and antigen presenting cells) based 
on side scatter chanel (SSC) vs FSC comparisons on previously ungated cells. Sample analysis of CD3+, CD4+, 
CD8+ populations were gated on singlet cells via SSC-W vs SSC-H, followed by further gating on lymphocytes 
via SSC vs FSC comparisons. PerCP-Cy5.5 was utilized as a dump channel to reduce background fluorescence in 
comparisons via PerCP-Cy5.5 vs APC comparisons. For total CD3+, CD4+, and CD8+ population comparisons, 
SSC was compared to APC, PeCy-7, and FITC respectively. Cell percentages were multiplied by total cells counted 
from organs by hemocytometer. For CD8+ pentamer+ analysis, CD3+ cells were gated in SSC vs APC-CD3 com-
parisons. Within the CD3+ cell gate, CD4+ and CD8+ cells were evaluated via PE-Cy7 vs FITC comparisons. 
CD8+ cells were gated and gB(498-505) (SSIEFARL) specificity was evaluated via PE-pentamer vs CD8+-FITC 
comparisons.
ELISpot assays. Skin was harvested from euthanized mice 6 days post-infection. Primary lesions were 
excised with 8 mm biopsy punches (Miltex, York, PA). Upper and lower secondary lesions were combined per 
mouse. Skin was incubated, dermis-side down, in Dispase (1 U/ml, Stemcell, Vancouver, BC, Canada) at 37 °C 
for 90 minutes in a 24-well plate. Skins were then incubated in Trypsin/EDTA at 37 °C for 30 minutes. Skin was 
roughly homogenized with a scalpel blade and incubated in solution containing 1 mg/ml Collagenase A (Roche, 
Pleasanton, CA) with 40 ug/ml DNase I (Roche) at 37 °C for 1 hour. PBS with 10% heat inactivated FBS was added 
to each sample. Skin cells were isolated through a 100 μm cell strainer into a 50 ml tube and washed with PBS. 
Cells were pelleted and resuspended in RPMI (Hyclone GE, Logan, UT) with 10% FBS, 2 mM l-glutamine, 1% 
antibiotic-antimycotic (Thermo Fisher Scientific) and 50 μM β-mercaptoethanol (Sigma-Aldrich, St. Louis, MO). 
Cells (3.25 × 105) were added to mouse CD4 + /IFN-γ specific ELISpot plate (R&D Systems, Minneapolis, MN) 
and processed as per manufacturer’s instructions. Cells were counted through visualization with a dissecting 
microscope.
RNA isolation and expression analyses. RNA was isolated from mouse skin using RNeasy Plus Universal 
minikit with genomic DNA eliminator step (Qiagen) according to manufacturer’s instructions. Human RNA was 
isolated using RNeasy minikit (Qiagen) in a similar manner. 1 μg per sample RNA was reverse-transcribed for 
1.5 hour using 1 μg oligo(dN)6, 5.5 U RNAguard Ribonuclease Inhibitor (GE Healthcare) and 10 U AMV reverse 
transcriptase (Promega, Madison, WI) according to manufacturer’s instructions. Inactivation of AMV was per-
formed at 95 °C for 10 minutes. The relative gene expression was quantified using real-time PCR with the compar-
ative ΔΔCt method utilizing either GAPDH or Actin as the housekeeping gene. For analyses of gene expression 
in mouse skin, the following primers were used: Mouse GAPDH-Forward, 5′ CTTGTGCAGTGCCAGCC 3′; 
Mouse GAPDH-Reverse, 5′ GCCCAATACGGCCAAATCC 3′; Mouse IL1F8-Forward, 5′ CACTATGCATGG 
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ATCCTCAC 3′; Mouse IL1F8-Reverse, 5′ TGTCTCTACATGCTATCAAGC 3′; Mouse IL1F6-Forward, 5′ GACC 
AGACGCTCATAGCAG 3′; Mouse IL1F6-Reverse, 5′ CTTTAGCACACATCAGGCAG 3′; Mouse IL1F9-Forward, 
5′ ATGGACACCCTACTTTGCTG 3′; Mouse IL1F9-Reverse, 5′ CAGGGTGGTGGTACAAATC 3′; Mouse 
Actin-Forward, 5′ CACCAGTTCGCCATGGAT 3′; Mouse Actin-Reverse, 5′ CATCACACCCTGGTGCCTA 3′. 
HSV-1 gD mRNA levels were determined using the primers and probe for HSV-1 genome copy number deter-
minations. Primers for human GAPDH, IL-36α, IL-36β and IL-36γ are listed elsewhere22, 68. Primers used to dis-
tinguish the two human IL-36β splice variants: IL1F8-F (common forward), 5′ TCTCTGTCTCTTCTGTGCAG 
3′; IL1F8-RA (reverse isoform 1), 5′ GCTCTCTCTCACATCCAGG 3′; IL1F8-RB (reverse isoform 2), 5′ 
GGCTTCTGTGCTTTCTTCTC 3′.
Computational and statistical analyses. Alignments were performed using Clustal omega tool 
from EMBL-EBI http://www.ebi.ac.uk/Tools/msa/clustalo/. Evolutionary analyses were conducted using the 
MEGA7 software http://www.megasoftware.net. The following sequences were used for protein alignments: 
hIL-36α, NP_055255.1; hIL-36β isoform 1, NP_055253.2; hIL-36β isoform 2, NP_775270.1; hIL-36γ isoform 1, 
NP_062564.1; hIL-36γ isoform 2, NP_001265497.1; mIL-36α, NP_062323.1; mIL-36β, NP_081439.1; mIL-36γ, 
NP_705731.2). All experiments were performed at least three times unless otherwise indicated. Statistical signifi-
cance was calculated using student’s t tests unless stated otherwise. All data shown are arithmetic means ± stand-
ard deviations unless indicated otherwise.
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